Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.

被引：0
|
作者：
Lian, Bin
Tian, Hui
Si, Lu
Chi, Zhihong
Sheng, Xinan
Wang, Xuan
Mao, Lili
Bai, Xue
Tang, Bixia
Yan, Xieqiao
Li, Siming
Zhou, Li
Wei, Xiaoting
Li, Juan
Li, Caili
Cui, Chuanliang
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Melanoma & Sarcoma, Beijing, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Dept Melanoma & Sarcoma, Beijing, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Genitourinary Oncol, Beijing, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Melanoma & Sarcoma Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9508
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 2 clinical trial of neoadjuvant anti-PD-1 ab (Toripalimab) plus axitinib in resectable mucosal melanoma.
    Cui, Chuanliang
    Wang, Xuan
    Lian, Bin
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Kong, Yan
    Mao, Lili
    Bai, Xue
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Zhou, Li
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Toripalimab (anti-PD-1) versus high-dose interferon-a2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
    Lian, B.
    Si, L.
    Chi, Z. H.
    Sheng, X. N.
    Kong, Y.
    Wang, X.
    Tian, H.
    Li, K.
    Mao, L. L.
    Bai, X.
    Tang, B. X.
    Yan, X. Q.
    Li, S. M.
    Zhou, L.
    Dai, J.
    Tang, X. W.
    Ran, F. W.
    Yao, S.
    Guo, J.
    Cui, C. L.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (10) : 1061 - 1070
  • [3] Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase randomized trial.
    Cui, Chuanliang
    Lian, Bin
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Kong, Yan
    Wang, Xuan
    Tian, Hui
    Mao, Lili
    Bai, Xue
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Zhou, Li
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy
    Jacques, S. K.
    McKeown, J.
    Grover, P.
    Park, B.
    Zaremba, A.
    Dimitriou, F.
    Rashid, M. F. Harunal
    Namikawa, K.
    Mooradian, M.
    Placzke, J.
    Allayous, C.
    Mehmi, I.
    DePalo, D.
    Wicky, A.
    Schwarze, J. K.
    Nakamura, Y.
    Benannoune, N.
    Menzies, A. M.
    Lo, S. N.
    Carlino, M. S.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S915 - S916
  • [5] Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
    Jacques, Sarah K.
    McKeown, Janet
    Grover, Piyush
    Johson, Douglas B.
    Zaremba, Anne
    Dimitriou, Florentia
    Weiser, Roi
    Farid, Mohamad
    Namikawa, Kenjiro
    Sullivan, Ryan J.
    Rutkowski, Piotr
    Lebbe, Celeste
    Hamid, Omid
    Zager, Jonathan S.
    Michielin, Olivier
    Neyns, Bart
    Nakamura, Yasuhiro
    Robert, Caroline
    Mehnert, Janice
    Ascierto, Paolo A.
    Bhave, Prachi
    Park, Benjamin
    Zimmer, Lisa
    Mangana, Joanna
    Mooradian, Megan
    Placzke, Joanna
    Allayous, Clare
    Oliva, Isabella C. Glitza
    Mehmi, Inderjit
    Depalo, Danielle
    Wicky, Alexandre
    Schwarze, Julia K.
    Roy, Severine
    Boatwright, Christina
    Vanella, Vito
    Long, Georgina, V
    Menzies, Alexander M.
    Lo, Serigne N.
    Carlino, Matteo S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 199
  • [6] The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma
    Mooradian, Meghan J. J.
    Sullivan, Ryan J. J.
    [J]. CANCER, 2023, 129 (14) : 2117 - 2121
  • [7] Adjuvant radiotherapy plus systemic chemotherapy in resected head and neck mucosal melanoma.
    Duan, Rong
    Tang, Bixia
    Chi, Zhihong
    Cui, Chuanliang
    Lian, Bin
    Li, Siming
    Mao, Lili
    Yan, Xieqiao
    Wang, Xuan
    Bai, Xue
    Zhou, Li
    Wei, Xiaoting
    Guo, Jun
    Sheng, Xinan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Toripalimab (anti-PD-1) plus recombinant human endostatin as adjuvant therapy in patients with resected stage III melanoma: Interim analysis of an open-label phase II trial.
    Hu, Xianglin
    Xu, Yu
    Sun, Yang-bai
    Yang, Ling-ge
    Zheng, Bi-qiang
    Sun, Zheng-Wang
    Chen, Yong
    Yan, Wangjun
    Wang, Chun-Meng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] A MULTICENTER CHARACTERIZATION OF CHRONIC TOXICITIES FOLLOWING ADJUVANT ANTI-PD-1 THERAPY FOR HIGH RISK RESECTED MELANOMA
    Patrinely, James
    Johnson, Rebecca
    Lawless, Aleigha
    Bhave, Prachi
    Sawyers, Amelia
    Dimitrova, Maya
    Yeohc, Hui
    Palmeri, Marisa
    Davis, Elizabeth
    Rapisuwon, Suthee
    Long, Georgina
    Haydon, Andrew
    Osman, Iman
    Mehnert, Janice
    Carlino, Matteo
    Sullivan, Ryan
    Menzies, Alexander
    Johnson, Douglas
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A114 - A115
  • [10] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
    Li, Mengqian
    [J]. LANCET ONCOLOGY, 2021, 22 (08): : E342 - E342
12345